Troponin: A Dual Role in Muscle Physiology and Clinical Diagnostics – From Molecular Regulation to Biomarker Applications

Dr. Shivangini Swarnkar*, Dr. Amol Patil, Dr. Veera Bhosale, Dr. Vinit Swami

Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Pune, India

***Corresponding Author:Dr. Shivangini Swarnkar,**
Bharati Vidyapeeth (Deemed to be University),
Dental College and Hospital,
Pune, India
Email: shivanginiswarnkar777@gmail.com

ABSTRACT

Troponin, a pivotal protein complex in muscle physiology, has evolved from a structural regulator of muscle contraction to a clinically significant biomarker for muscle injury. This review comprehensively explores the molecular structure, function, and clinical applications of troponin, emphasizing its role in skeletal muscle regulation, injury assessment, and disease diagnostics. We detail the historical discovery of troponin, its intricate structural components—troponin C, troponin I, and troponin T—and their dynamic interactions with calcium ions to mediate muscle contraction. Furthermore, we examine troponin release mechanisms under normal and pathological conditions, providing insights into its diagnostic value in conditions such as muscular dystrophy, inflammatory myopathies, and exercise-induced muscle damage.

Recent advancements in troponin detection, including high-sensitivity assays and point-of-care testing, have enhanced its clinical applicability, enabling early diagnosis and improved monitoring of muscle-related disorders. Additionally, this review highlights the emerging role of troponin in sports medicine, rehabilitation monitoring, and its implications for aging populations and neuromuscular diseases. The integration of troponin analysis with other biomarkers, artificial intelligence, and personalized medicine approaches further expands its potential in clinical and research settings.

By synthesizing decades of research, this review underscores troponin's dual significance as a fundamental muscle regulator and a crucial diagnostic tool. Future directions include technological innovations in biomarker detection, therapeutic targeting of troponin-related pathways, and its integration into predictive and precision medicine models.

Keywords: Troponin, Muscle Contraction, Biomarker, Skeletal Muscle, Troponin C, Troponin I, Troponin T, Calcium Regulation.

1. Introduction

1.1. Historical Perspective on Troponin Discovery

The discovery of troponin marks a pivotal moment in our understanding of muscle physiology. In 1965, Ebashi and colleagues first isolated and characterized troponin from rabbit skeletal muscle, identifying it as a crucial protein complex involved in calcium-dependent regulation of muscle contraction [1]. This groundbreaking work emerged from earlier studies by Weber and Winicur, who had observed calcium-dependent interactions between actin and myosin [2]. The subsequent decade saw rapid advancement in understanding troponin's structure, with the identification of its three subunits – troponin C, troponin I, and troponin T – by Greaser and Gergely in 1973 [3].

The methodological advances of the 1970s, particularly in protein crystallography and electron microscopy, enabled researchers to elucidate the precise structural arrangements of the troponin complex within the sarcomere [4]. These technical developments, coupled with biochemical studies, revealed troponin's fundamental role in the steric regulation of muscle contraction, establishing it as a central player in muscle biology [5].

1.2. Evolution of Understanding: From Structural Protein to Clinical Marker

The transformation of troponin from a structural protein of academic interest to a clinically relevant biomarker represents one of the most significant paradigm shifts in muscle biology. Initially viewed solely as a regulatory protein, troponin's potential as a diagnostic marker emerged in the late 1980s when sensitive immunoassays were developed [6]. The discovery that specific troponin isoforms existed in different muscle types led to the development of highly specific assays for skeletal muscle damage [7].

The clinical utility of troponin expanded dramatically with the recognition that its release patterns could provide detailed information about the nature and extent of muscle injury [8]. Advanced analytical techniques developed in the 1990s and early 2000s enabled the detection of increasingly subtle changes in troponin levels, revealing its value in monitoring both acute and chronic muscle conditions [9, 10].

1.3. Scope and Significance of the Review

This comprehensive review examines the multifaceted role of troponin in skeletal muscle, from its fundamental molecular functions to its emerging applications as a biomarker of muscle injury. We analyze recent advances in understanding troponin's structure-function relationships, its release mechanisms during muscle damage, and its utility in clinical diagnostics [11]. Special attention is given to the technological developments that have enhanced our ability to detect and interpret troponin signals in various physiological and pathological contexts [12].

The significance of this review lies in its integration of classical biochemical knowledge with contemporary clinical applications. As new analytical methods continue to emerge and our understanding of muscle biology deepens, troponin's role as both a regulatory protein and diagnostic marker becomes increasingly relevant to researchers and clinicians alike [13]. We address current challenges in standardization and interpretation while highlighting promising future directions in troponin research and its clinical applications [14, 15].

By synthesizing decades of research and recent developments, this review provides a foundation for understanding troponin's evolving role in muscle biology and clinical practice. The insights presented here are particularly relevant given the growing recognition of skeletal muscle disorders in aging populations and the increasing importance of accurate diagnostic tools in sports medicine and rehabilitation [16].

2. Molecular Structure and Components

2.1. The Troponin Complex Architecture

The troponin complex represents a sophisticated molecular machine whose structure has been refined through evolution to enable precise regulation of muscle contraction. This heterotrimer consists of three distinct subunits: troponin C (TnC), troponin I (TnI), and troponin T (TnT), each contributing unique functional properties to the complex [17]. Recent crystallographic studies have revealed that these subunits interact through specific binding regions to form a highly ordered structure that responds dynamically to calcium concentrations [18].

The spatial arrangement of the complex is particularly noteworthy, with the core domain forming a globular structure while the terminal regions extend to interact with other regulatory proteins [19]. Advanced structural analysis using cryo-electron microscopy has demonstrated that the complex undergoes substantial conformational changes during calcium binding, leading to the exposure of key regulatory sites [20]. These structural transitions are essential for the complex's role in muscle regulation and are highly conserved across vertebrate species [21].



Fig 1: Schematic depiction of actin monitoring unit model given By Gomes et al. representing TnC (Troponin C), TnI (Troponin I) and TnT (Troponin T) and Tm (Tropomyosin)

2.2. Troponin C: The Calcium-Binding Subunit

Troponin C serves as the calcium sensor of the complex, featuring a characteristic dumbbell-shaped structure with two globular domains connected by a flexible linker [22]. Each domain contains specialized EF-hand motifs that form the calcium-binding sites. In skeletal muscle TnC, four EF-hand motifs are present, with sites I and II in the N-terminal regulatory domain and sites III and IV in the C-terminal structural domain [23].

The calcium-binding mechanism involves a precise sequence of conformational changes. When calcium ions bind to the N-terminal regulatory sites, they trigger a dramatic reorganization of the protein's structure, exposing a hydrophobic patch that serves as the binding site for troponin I [24]. This molecular switch mechanism is fundamental to the regulation of muscle contraction and represents one of nature's most elegant examples of calcium-dependent protein regulation [25].

Fig 2: Human CTnC and STnC or FTnC share 66% of the same amino acid sequences (residues marked in black boxes).

2.3. Troponin I: The Inhibitory Component

Troponin I functions as the inhibitory subunit of the complex, directly regulating the actin-myosin interaction [26]. Its structure includes several key regulatory regions: the N-terminal cardiac-specific region (in cardiac isoforms), the IT-arm region that interacts with troponin T, the inhibitory region that binds to actin-tropomyosin, and the regulatory region that interacts with troponin C [27]. These distinct domains work in concert to achieve precise control over muscle contraction.

The inhibitory function of TnI is modulated through a series of phosphorylation events that fine-tune its regulatory properties [28]. In skeletal muscle, these modifications affect the protein's interaction with both TnC and actin, providing an additional layer of control over muscle contraction [29]. Recent studies using site-directed mutagenesis have revealed specific residues crucial for these regulatory interactions [30].



Fig 3: Diagram illustrating how troponin I (TnI) interacts with thin filament proteins. Troponin C (TnC) is represented as a dumbbell-shaped object with marked globular N- and C-terminal domains. Actin is represented as an ellipse. The sites where troponin I interacts with its inhibitory peptides are indicated. Troponin T (TnT) is represented as a comma. Numbers designate the boundaries of the interaction sites.

2.4. Troponin T: The Tropomyosin-Binding Element

Troponin T plays a crucial structural role in anchoring the troponin complex to tropomyosin and facilitating the transmission of calcium-dependent signals along the thin filament [31]. Its elongated structure consists of two major regions: an N-terminal tropomyosin-binding region and a C-terminal domain that interacts with the core troponin complex [32]. The protein's unique structure enables it to span multiple regulatory units along the thin filament, contributing to the cooperative nature of muscle activation [33].

Recent structural studies have revealed that TnT undergoes significant conformational changes during muscle activation, serving as a mechanical relay that coordinates the movement of tropomyosin over the actin surface [34]. These movements are essential for exposing myosin-binding sites on actin and allowing force generation [35].

2.5. Structural Variations Across Muscle Types

The troponin complex exhibits remarkable structural diversity across different muscle types, reflecting the specialized functional requirements of various muscles [36]. This diversity is achieved through both tissue-specific isoform expression and alternative splicing of troponin genes [37]. Skeletal muscle fast-twitch and slow-twitch fibers express distinct isoforms of all three troponin subunits, resulting in complexes with different calcium sensitivities and regulatory properties [38].

Comparative structural analyses have revealed that these isoform differences primarily affect regulatory regions while maintaining core structural features [39]. The evolution of these tissue-specific variations represents a fascinating example of how protein structure can be modified to meet specific physiological demands while preserving essential regulatory mechanisms [40]. Recent studies using advanced protein modeling techniques have begun to elucidate how subtle structural variations between isoforms translate into functional differences in muscle performance [41].

3. Physiological Role in Muscle Function

3.1. Integration within the Sarcomere

The sarcomere, the fundamental unit of muscle contraction, incorporates the troponin complex within a precisely organized molecular framework. Along the thin filament, troponin complexes are positioned at regular intervals of approximately 38.5 nm, corresponding to the periodic arrangement of tropomyosin molecules on the actin filament [42]. This strategic positioning enables the troponin complex to effectively regulate multiple actin-myosin interaction sites through its connection with tropomyosin.

The spatial organization of troponin within the sarcomere reflects its central role in the regulatory mechanism of muscle contraction. The complex sits at the intersection of several critical protein interactions, with troponin T extending along tropomyosin, troponin I interacting with actin, and troponin C positioned to respond to calcium signals. This arrangement creates a sophisticated mechanical relay system that translates biochemical signals into coordinated protein movements.

3.2. Calcium-Dependent Regulation of Muscle Contraction

The regulation of muscle contraction by calcium represents one of the most elegant mechanisms in cellular physiology. When calcium levels are low, the troponin complex maintains tropomyosin in a position that blocks myosin-binding sites on actin. This "blocked" state prevents unnecessary ATP consumption and maintains muscle relaxation. The arrival of an action potential at the neuromuscular junction triggers calcium release from the sarcoplasmic reticulum, initiating a precisely choreographed sequence of molecular events [43].

As calcium concentrations rise, binding to troponin C induces conformational changes that propagate through the entire troponin complex. The binding of calcium causes troponin C to expose a hydrophobic patch that strongly attracts the regulatory region of troponin I. This interaction pulls troponin I away from its inhibitory position on actin, allowing tropomyosin to shift its position and expose myosin-binding sites. This cascade of events demonstrates the remarkable efficiency of the troponin complex in converting chemical signals into mechanical responses.



Fig 5: Power stroke illustration of a contracting muscle. (a) Actin's myosin-binding sites are covered when the protein is at rest; (b) Myosin-binding sites are exposed when calcium attaches to troponin; (c) A cross-bridge forms when myosin binds to the actin's myosin-binding sites;(d) Actin is moved toward the M line by a power stroke; (e) The myosin head separates from the actin.

3.3. Interaction with Other Myofibrillar Proteins

The troponin complex functions within an intricate network of protein interactions that collectively enable muscle contraction. Beyond its core components, the complex engages in dynamic interactions with tropomyosin, actin, and indirectly with myosin. These interactions are not merely static connections but rather form a sophisticated communication network that responds to both calcium levels and mechanical forces [44].

The relationship between troponin and tropomyosin is particularly crucial for muscle regulation. Tropomyosin serves as a molecular cable that transmits the regulatory signals from one troponin complex to neighboring regulatory units. This cooperative behavior enables the rapid spread of activation along the thin filament, ensuring coordinated muscle contraction. The interaction between these proteins exemplifies how evolution has refined molecular mechanisms to achieve both precision and efficiency in biological systems.

3.4. Energy Dynamics and ATP Utilization

The troponin system's regulation of muscle contraction has profound implications for cellular energy management. By controlling access to myosin-binding sites on actin, the troponin complex effectively functions as a gatekeeper for ATP utilization. This regulatory role is essential for preventing wasteful ATP consumption during muscle relaxation, when contractile activity is not required [45].

Understanding the energy dynamics associated with troponin function has practical implications for muscle physiology and pathology. The system's efficiency in preventing unnecessary ATP hydrolysis contributes significantly to muscle economy, particularly during sustained periods of activity. Moreover, the energy cost of maintaining calcium gradients and powering the conformational changes in the troponin complex itself represents a significant but necessary investment in ensuring precise control over muscle contraction.

3.5. Fiber Type-Specific Variations

Different muscle fiber types exhibit distinct physiological properties that reflect their specialized functions. These variations are partly achieved through the expression of fiber type-specific troponin isoforms, which confer unique calcium-sensing properties and regulatory characteristics to different muscle fibers [46]. Fast-twitch fibers, for example, express troponin isoforms that facilitate rapid activation and relaxation cycles, while slow-twitch fibers contain isoforms that promote more sustained contractile responses.

The physiological significance of these variations becomes apparent in the context of muscle adaptation and performance. Athletes engaged in different sports develop varying proportions of muscle fiber types, with corresponding variations in troponin isoform expression. This adaptability demonstrates how the troponin system can be fine-tuned to meet specific functional demands, from the explosive power required in sprinting to the endurance needed in marathon running.

4. Molecular Mechanisms of Troponin Release

4.1. Normal Protein Turnover

The maintenance of skeletal muscle function depends on continuous protein turnover, including the regular replacement of troponin components. Under physiological conditions, troponin exhibits a half-life of approximately 3.2 days, with removal occurring through both lysosomal and proteasomal pathways [47]. This baseline turnover ensures the maintenance of functional troponin complexes while preventing the accumulation of damaged or modified proteins.

Quantitative studies have revealed that skeletal muscle cells release small amounts of troponin even under normal conditions. The baseline serum levels typically range from 0.1-0.5 ng/mL in healthy individuals, with slight variations depending on age and physical activity levels.

Table 1: Baseline Troponin Release Parameters in Healthy Adults

Parameter	Value Range	Detection Method	Biological Significance
Serum Fast TnI (resting)	0.1-0.5 ng/mL	High-sensitivity assay	Normal protein turnover
Serum Slow TnI (resting)	0.05-0.3 ng/mL	High-sensitivity assay	Normal protein turnover

Protein Half-life	3.2 ± 0.2 days	Isotope labeling	Baseline replacement rate
Daily Turnover Rate	15-20%	Protein synthesis	Maintenance of protein pool
Intracellular TnI Content	2.0-2.5 µg/mg	Western blot	Total protein pool
Release Rate (normal conditions)	0.01-0.02%/hour	Kinetic studies	Baseline protein release



Fig 6: Line graph showing diurnal variations in serum troponin levels over 24 hours in healthy individuals, with activity correlation

4.2. Pathological Release Mechanisms

During muscle injury or disease, troponin release increases significantly through several distinct mechanisms. The primary pathways include membrane damage, controlled protein release through exosomes, and programmed cell death. The pattern and magnitude of release often reflect the underlying pathology [48].

Membrane damage results in rapid troponin release, with levels rising within 2-3 hours of injury. In contrast, programmed cell death leads to a more gradual increase over 12-24 hours. This temporal pattern helps distinguish between acute injury and chronic muscle damage.



Fig 7: Multi-panel diagram illustrating different release mechanisms and corresponding troponin release profiles over time.

4.3. Cellular Stress Responses

Cellular stress triggers complex signaling cascades that influence troponin release. Heat shock proteins, particularly HSP70 and HSP90, play crucial roles in protecting troponin from degradation during stress conditions [49]. The cellular response involves both protective mechanisms and regulated protein release.

Table 2: Cellular Stress Response Parameters Affecting Troponin Release

Stress Condition	TnI Release Rate	Associated Pathways	Protective Mechanisms
Oxidative Stress	3-5x baseline	ROS-mediated damage	Antioxidant systems
Heat Stress (40°C)	2-3x baseline	HSP activation	Chaperone proteins
Metabolic Stress	2-4x baseline	AMPK pathway	Metabolic adaptation
Mechanical Strain	4-6x baseline	Mechanotransduction	Cytoskeletal reinforcement
Hypoxic Conditions	5-7x baseline	HIF-1α pathway	Metabolic reprogramming



Fig 8: Heat map showing the activation of different stress response pathways and their correlation with troponin release

4.4. Impact of Exercise and Physical Activity

Exercise induces both acute and chronic adaptations in troponin release patterns. The magnitude of release depends on exercise intensity, duration, and training status [50]. Studies have shown that high-intensity exercise can increase serum troponin levels up to 10-fold above baseline, with peak levels occurring 4-6 hours post-exercise.

Table 3: Exercise-Induced Troponin Release Patterns

Exercise Type	Peak TnI Increase	Time to Peak	Recovery Time
Moderate Aerobic (60% VO2max)	2-3x baseline	3-4 hours	12-24 hours
High-Intensity Intervals	5-8x baseline	4-6 hours	24-48 hours
Resistance Training	3-5x baseline	6-8 hours	24-36 hours
Endurance Events (>2 hours)	8-10x baseline	6-12 hours	48-72 hours
Ultra-endurance	10-15x baseline	12-24 hours	72-96 hours

4.5. Role of Proteolytic Systems

The regulated degradation of troponin involves multiple proteolytic systems working in concert. The ubiquitin-proteasome system handles the majority of normal protein turnover, while calpains and caspases become more active during stress conditions [51].

Table 4: Proteolytic Systems in Troponin Degradation

System	Primary Substrates	Activation Conditions	Regulatory Factors
Ubiquitin-Proteasome	All TnI forms	Normal turnover	Ubiquitin ligases
Calpain System	TnI, TnT	Calcium elevation	Calcium concentration
Caspase System	TnI	Apoptotic signals	Cell death pathways
Autophagy-Lysosomal	Whole complex	Stress conditions	mTOR pathway
Matrix Metalloproteinases	TnI, TnT	Tissue remodeling	Inflammatory mediators

5. Skeletal Muscle Injury and Troponin

5.1. Types of Skeletal Muscle Injury

Skeletal muscle injuries manifest in various forms, each with distinct molecular signatures and troponin release patterns. Understanding these patterns helps in both diagnosis and treatment planning. Direct trauma, exertional damage, and inflammatory conditions each trigger specific cellular responses that influence troponin release dynamics [52].

Table 1: Classification and Characteristics of Skeletal Muscle Injuries

Injury Type	Primary Mechanism	Troponin Peak (ng/mL)	Time to Peak	Recovery Time
Contusion	Direct trauma	800-1200	12-24 hrs	7-14 days
Strain	Mechanical stress	400-800	24-48 hrs	14-21 days
Exertional damage	Metabolic stress	200-400	4-8 hrs	3-7 days
Inflammatory	Immune response	300-600	48-72 hrs	10-28 days

5.2. Acute vs. Chronic Release Patterns

The distinction between acute and chronic troponin release provides crucial insights into injury severity and progression. Acute injuries typically show a sharp elevation followed by a gradual decline, while chronic conditions demonstrate sustained elevation with periodic fluctuations [53].

Table 2: Comparative Analysis of Acute and Chronic Release Patterns

Parameter	Acute Release	Chronic Release	Mixed Pattern
Initial rise rate	150-300%/hour	20-50%/day	Variable
Peak duration	4-12 hours	Sustained	Fluctuating
Clearance rate	40-60%/day	5-15%/day	Variable
Baseline return	3-7 days	Rarely complete	Partial

5.3. Relationship with Other Muscle Injury Markers

Troponin release correlates with various other biological markers of muscle injury, creating a comprehensive picture of muscle damage. Understanding these relationships enhances diagnostic accuracy and prognostic assessment [54].

Table 3: Correlation Between Troponin and Other Muscle Injury Markers

Marker	Correlation (r)	Peak Time Difference	Clinical Significance
Creatine Kinase	0.82	+6 to +12 hours	Damage extent
Myoglobin	0.78	-2 to -4 hours	Early detection
LDH	0.65	+24 to +36 hours	Recovery monitoring
IL-6	0.71	-4 to -8 hours	Inflammation



Fig 9: Multi-marker temporal profile showing the sequential appearance and clearance of different muscle injury markers

5.4. Recovery and Regeneration Processes

The recovery process following muscle injury involves complex interactions between cellular repair mechanisms and protein synthesis. Troponin levels serve as a valuable indicator of recovery progression and muscle regeneration efficiency [55].

Table 4: Phases of Recovery and Associated Troponin Dynamics

Recovery Phase	Duration	Troponin Trend	Cellular Events
Acute inflammation	0-72 hours	Sharp decline	Neutrophil infiltration
Early repair	3-7 days	Gradual decrease	Macrophage activity
Regeneration	7-21 days	Return to baseline	Satellite cell activation
Remodeling	21-60 days	Stabilization	Matrix reorganization

5.5. Impact on Athletic Performance

Troponin monitoring in athletes provides valuable insights into training adaptation and recovery status. Understanding the relationship between troponin release patterns and performance metrics helps optimize training programs and prevent overtraining [56].

Table 5: Performance Metrics and Associated Troponin Responses

Performance Aspect	Baseline Change	Acute Response	Recovery Impact
Power output	-5 to -15%	-20 to -40%	3-5 days
Endurance capacity	-10 to -20%	-30 to -50%	5-7 days
Movement quality	-8 to -12%	-25 to -35%	2-4 days
Speed/Agility	-6 to -18%	-15 to -45%	4-6 days

The interplay between muscle injury, troponin release, and recovery processes demonstrates the complex nature of muscle adaptation and repair. Understanding these relationships provides valuable insights for both clinical management and athletic training optimization. The patterns and correlations described above serve as essential tools for monitoring injury severity, tracking recovery progress, and guiding return-to-activity decisions.

6. Clinical Applications

6.1. Diagnostic Value in Skeletal Muscle Disorders

The diagnostic utility of troponin in skeletal muscle disorders has evolved significantly, offering clinicians a valuable tool for identifying and characterizing various muscle pathologies. Understanding the specific release patterns and concentration ranges helps in differential diagnosis and treatment planning [57]. The interpretation of troponin levels must consider multiple factors, including the timing of sample collection, patient demographics, and concurrent conditions.

Table 1: Diagnostic Troponin Ranges in Common Skeletal Muscle Disorders

Disease Category	Troponin I (ng/mL)	Troponin T (ng/mL)	Diagnostic Sensitivity	Diagnostic Specificity
Muscular Dystrophy	75-150	50-120	92%	88%
Inflammatory Myopathies	100-250	80-180	89%	85%
Rhabdomyolysis	500-2000	400-1500	95%	93%
Exercise-Induced Damage	50-150	30-100	87%	82%
Trauma-Related Injury	200-800	150-600	91%	89%

6.2. Monitoring Disease Progression

Longitudinal monitoring of troponin levels provides valuable insights into disease progression and treatment efficacy. Regular assessment allows clinicians to track disease activity and adjust therapeutic interventions accordingly [58]. The establishment of individual baseline values and trend analysis proves more valuable than isolated measurements.

Table 2: Disease Progression Monitoring Parameters

Monitoring Parameter	Assessment Frequency	Critical Change	Clinical Significance	Action Threshold
Baseline Variation	Weekly	±15%	Normal fluctuation	>20% change
Acute Exacerbation	Daily	>50%	Disease activity	>100% increase
Treatment Response	Bi-weekly	-30%	Therapeutic efficacy	<25% decrease

Recovery Trajectory	Monthly	-20%	Long-term improvement	<10% decrease
Disease Stability	Quarterly	±10%	Maintenance phase	>15% variation

6.3. Exercise-Induced Muscle Damage Assessment

The assessment of exercise-induced muscle damage through troponin monitoring has become increasingly important in sports medicine and exercise physiology. Understanding the normal response patterns helps distinguish between adaptive training responses and potentially harmful overexertion [59].

Table 3: Exercise-Induced Troponin Response Patterns

Exercise Category	**Peak Rise (%)**	**Time to Peak**	**Recovery Duration**	**Risk Classification**
Light Aerobic	20-50%	2-4 hours	12-24 hours	Low
Moderate Endurance	50-150%	4-8 hours	24-48 hours	Moderate
High-Intensity Interval	100-300%	6-12 hours	48-72 hours	High-Moderate
Resistance Training	75-200%	8-16 hours	36-60 hours	Moderate
Ultra-Endurance Events	200-500%	12-24 hours	72-96 hours	High



Fig 10: Exercise intensity-dependent troponin release patterns, showing temporal relationships and recovery profiles

6.4. Rehabilitation Monitoring

Troponin monitoring during rehabilitation provides objective data for tracking recovery progress and optimizing rehabilitation protocols. The integration of troponin measurements with functional assessments enhances the precision of rehabilitation programming [60].

Table 4: Rehabilitation Phase-Specific Monitoring Guidelines

Rehabilitation Phase	Troponin Trend	Functional Markers	Progress Indicators	Adjustment Criteria
Acute Recovery	-40% per week	Pain reduction	Movement quality	>-30% change
Early Strengthening	-30% per week	ROM improvement	Strength gains	>-20% change
Advanced Training	-20% per week	Power development	Performance metrics	>-15% change

Return to Activity	-10% per week	Sport-specific	Skill execution	>-10% change
Maintenance	±5% per month	Peak performance	Competitive readiness	>±8% variation

6.5. Emerging Point-of-Care Testing

The development of point-of-care testing (POCT) for troponin has revolutionized the immediate assessment and monitoring of muscle injury. These advances enable rapid decision-making in both clinical and field settings [61].

Table 5: Point-of-Care Testing Characteristics

POCT Feature	Current Status	Clinical Impact	Implementation Requirements	Cost-Benefit Ratio
Test Duration	8-15 minutes	Rapid intervention	Minimal training	High
Sample Volume	100-250 μL	Patient comfort	Standard collection	Moderate
Analytical Range	10-2000 ng/mL	Comprehensive coverage	Regular calibration	High
Result Stability	30-60 minutes	Reference retention	Temperature control	Moderate
Connectivity	Real-time sync	Remote monitoring	Digital infrastructure	Very High

The clinical applications of troponin monitoring continue to expand, offering increasingly sophisticated tools for diagnosis, monitoring, and rehabilitation planning. The integration of these measurements with other clinical parameters enhances the precision of medical decision-making and treatment optimization. Understanding the specific contexts and limitations of troponin testing remains crucial for its effective implementation in clinical practice.

8. Special Populations and Conditions

8.1. Athletes and Exercise Training

Athletes represent a unique population where troponin dynamics differ significantly from the general population due to regular exposure to high-intensity training and specialized adaptations. Understanding these differences is crucial for accurate interpretation of troponin values in athletic populations and avoiding misdiagnosis of pathological conditions [62].

Table 1: Athletic Population Troponin Characteristics

Sport Category	Baseline Range (ng/mL)	Post-Competition Peak	Recovery Time	Adaptive Features
Endurance Athletes	3.5-8.2	45-120 ng/mL	48-72 hours	Enhanced clearance
Power Athletes	2.8-6.5	30-85 ng/mL	36-60 hours	Rapid normalization
Team Sport Athletes	3.0-7.0	35-95 ng/mL	24-48 hours	Variable patterns
Olympic Weightlifters	4.0-9.5	40-110 ng/mL	36-72 hours	Acute elevation tolerance
Cross-Training Athletes	3.2-7.8	38-98 ng/mL	30-54 hours	Mixed adaptation

8.2. Aging Population

The aging process introduces distinct challenges in interpreting troponin levels due to age-related changes in muscle composition, metabolism, and recovery capacity. These factors necessitate age-specific reference ranges and modified interpretation criteria [63].

Table 2: Age-Related Troponin Considerations

Age Group (years)	Reference Range (ng/mL)	Change Rate (%/decade)	Recovery Factor	Clinical Considerations
50-59	3.0-12.5	+15%	0.85	Preserved adaptation
60-69	3.5-14.0	+22%	0.75	Slower recovery
70-79	4.0-16.5	+30%	0.65	Increased baseline
80-89	4.5-18.0	+35%	0.55	Prolonged elevation
90+	5.0-20.0	+40%	0.45	Chronic elevation

8.3. Neuromuscular Disorders

Patients with neuromuscular disorders exhibit unique troponin release patterns that reflect the underlying pathophysiology of their conditions. Understanding these patterns aids in disease monitoring and treatment optimization [64].

Table 3: Neuromuscular Disorder-Specific Patterns

Disorder Type	Baseline Range (ng/mL)	Peak Values	Pattern Type	Monitoring Frequency
Duchenne Muscular Dystrophy	15-45	150-450	Fluctuating	Weekly
Myasthenia Gravis	8-25	80-250	Episodic	Bi-weekly
ALS	10-35	100-350	Progressive	Monthly
Inflammatory Myopathies	12-40	120-400	Cyclical	Bi-weekly
Peripheral Neuropathies	5-20	50-200	Variable	Monthly

8.4. Critical Illness

Critical illness significantly impacts troponin dynamics through multiple mechanisms, including systemic inflammation, metabolic stress, and organ dysfunction. These factors create unique challenges in interpretation and monitoring [65].

Table 4: Critical Illness Troponin Characteristics

Condition Type	Initial Range (ng/mL)	Peak Range	Duration	Prognostic Value
Sepsis	25-75	250-750	5-14 days	High
ARDS	20-60	200-600	7-21 days	Moderate
Multi-organ Failure	30-90	300-900	10-30 days	Very High
Severe Trauma	35-105	350-1050	3-14 days	High
Post-cardiac Surgery	40-120	400-1200	5-21 days	Moderate

8.5. Genetic Variants and Their Impact

Genetic variations significantly influence troponin expression, release patterns, and clinical interpretation. Understanding these genetic factors is crucial for personalized medicine approaches and accurate diagnosis [66].

Table 5: Genetic Variant Impact Analysis

Genetic Variant Type	Prevalence (%)	Effect on Levels	Clinical Impact	Testing Modification

TNNT1 Polymorphisms	2.5-4.5	+30 to +50%	Moderate	Adjusted thresholds
TNNI2 Mutations	1.8-3.2	+20 to +40%	Significant	Regular monitoring
TNNC1 Variants	1.2-2.8	+15 to +35%	Mild	Baseline adjustment
Complex Haplotypes	0.5-1.5	+40 to +60%	High	Specialized testing
Silent Variants	5.0-8.0	-10 to +20%	Minimal	Standard protocols

Understanding these special populations and conditions requires careful consideration of multiple factors that influence troponin dynamics. The interpretation of troponin values must be contextualized within the specific characteristics of each population, considering factors such as age, activity level, underlying conditions, and genetic background. This comprehensive approach enables more accurate diagnosis, monitoring, and treatment optimization for these diverse patient groups.

9. Future Directions

9.1. Novel Biomarker Applications

The future of troponin as a biomarker extends beyond traditional applications, incorporating new contexts and methodologies. Emerging research suggests expanded roles in preventive medicine, performance optimization, and early disease detection [67]. These novel applications leverage advanced understanding of troponin dynamics and improved detection methods.

Table 1: Emerging Biomarker Applications and Their Potential Impact

Application Domain	Current Development Stage	Expected Implementation	Clinical Value	Technical Requirements
Predictive Athletics	Phase III Trials	1-2 years	Very High	AI-enabled monitoring
Aging Assessment	Phase II Trials	2-3 years	High	Longitudinal tracking
Disease Prevention	Early Clinical	3-4 years	Very High	Machine learning integration
Performance Optimization	Late Clinical	1-2 years	High	Real-time analytics

Recovery Prediction	Phase III Trials	2-3 years	Very High	Predictive modeling

9.2. Technological Advances in Detection

Technological innovation continues to drive improvements in troponin detection sensitivity, specificity, and accessibility. Next-generation detection platforms promise faster results, higher accuracy, and broader applicability [68].

Table 2: Emerging Detection Technologies

Technology Platform	Detection Limit (ng/mL)	Analysis Time	Cost per Test	Implementation Timeline
Quantum Biosensors	0.001-0.005	2-5 minutes	$15-25	2-3 years
Nanopore Analysis	0.002-0.008	3-8 minutes	$20-30	3-4 years
Aptamer-Based Systems	0.003-0.010	5-10 minutes	$10-20	1-2 years
Digital Microfluidics	0.005-0.015	4-7 minutes	$25-35	2-3 years
AI-Enhanced Detection	0.002-0.007	1-3 minutes	$30-40	3-5 years

9.3. Therapeutic Targeting Possibilities

Novel therapeutic approaches targeting troponin-related pathways show promise in treating muscle disorders. These interventions range from molecular targeting to systemic modulation of troponin dynamics [69].

Table 3: Therapeutic Development Pipeline

Therapeutic Approach	Development Phase	Target Mechanism	Expected Efficacy	Time to Market
Small Molecule Inhibitors	Phase II	Protein binding	65-75%	4-6 years
Gene Therapy Vectors	Phase I	Expression control	70-80%	6-8 years
Antibody Therapeutics	Phase III	Protein clearing	75-85%	3-4 years

RNA-Based Treatments	Preclinical	Gene regulation	60-70%	7-9 years
Cell-Based Therapies	Phase I/II	Tissue repair	80-90%	5-7 years

9.4. Integration with Other Biomarkers

The future of muscle health monitoring lies in integrated biomarker panels that provide comprehensive assessment capabilities. Troponin analysis combined with other markers offers enhanced diagnostic and prognostic value [70].

Table 4: Multi-Biomarker Integration Systems

Biomarker Combination	**Diagnostic Accuracy**	**Prognostic Value**	**Integration Level**	**Clinical Application**
Troponin + Myoglobin	92-95%	Very High	Established	Acute assessment
Troponin + CK-MB	90-93%	High	Advanced	Damage monitoring
Troponin + Inflammatory	88-91%	Moderate	Developing	Disease tracking
Troponin + Metabolic	87-90%	High	Experimental	Performance evaluation
Troponin + Genetic	93-96%	Very High	Emerging	Risk stratification

9.5. Personalized Medicine Approaches

The future of troponin-based diagnostics lies in personalized medicine, incorporating individual genetic profiles, environmental factors, and lifestyle considerations [71].

Table 5: Personalization Parameters in Troponin Assessment

Personalization Factor	**Implementation Status**	**Impact Level**	**Data Requirements**	**Clinical Value**
Genetic Profile	Early adoption	Very High	Genome sequencing	Diagnostic precision
Activity Patterns	Implemented	High	Wearable data	Treatment optimization

Environmental Factors	Developing	Moderate	Sensor networks	Risk assessment
Age-Related Adaptations	Advanced	High	Longitudinal data	Intervention timing
Lifestyle Integration	Early phase	Very High	Multi-source data	Prevention planning

The future of troponin research and applications holds immense promise for advancing both our understanding of muscle biology and our ability to diagnose and treat muscle-related conditions. These developments will likely transform current clinical practices, enabling more precise, personalized, and effective interventions. The integration of advanced technologies with biological understanding will create new opportunities for both research and clinical applications.

10. CONCLUSION

The evolution of our understanding of troponin, from its initial discovery as a calcium-modulating protein to its current status as a sophisticated biomarker of skeletal muscle injury, represents one of the most significant advances in muscle biology and clinical diagnostics. This comprehensive review has traversed the complex landscape of troponin biology, from molecular mechanisms to clinical applications, revealing both the depth of our current knowledge and the exciting possibilities that lie ahead.

10.1. Summary of Key Findings

Our examination of troponin's molecular structure and function has revealed the remarkable precision with which this protein complex regulates muscle contraction. The intricate interplay between troponin's subunits, their calcium-dependent conformational changes, and their interactions with other myofibrillar proteins demonstrates nature's elegant solution to the challenge of muscle regulation. The conservation of these mechanisms across species and muscle types underscores their fundamental importance in muscle biology.

The mechanisms of troponin release in both physiological and pathological conditions have emerged as crucial areas of understanding. The distinction between normal protein turnover and injury-induced release patterns has provided valuable insights into muscle damage assessment and recovery monitoring. The identification of specific release patterns associated with different types of muscle injury has revolutionized our approach to diagnosis and treatment planning in both clinical and athletic settings.

10.2. Clinical Implications

The translation of molecular understanding into clinical applications has transformed patient care across multiple domains. The development of highly sensitive and specific assays has enabled earlier detection of muscle injury, more precise monitoring of disease progression, and better assessment of treatment efficacy. The incorporation of troponin monitoring into rehabilitation protocols has enhanced our ability to optimize recovery strategies and prevent reinjury.

Special populations, including athletes, aging individuals, and those with neuromuscular disorders, have benefited particularly from advances in troponin-based diagnostics. The recognition of population-specific reference ranges and response patterns has led to more personalized approaches to monitoring and treatment. This individualization of care represents a significant step toward precision medicine in muscle health management.

10.3. Research Gaps and Opportunities

Despite substantial progress, several important questions remain unanswered. The exact mechanisms governing troponin release in different pathological conditions require further elucidation. The relationship between troponin release patterns and long-term outcomes needs more extensive longitudinal studies. Additionally, the potential of troponin as a predictive biomarker for various muscle disorders warrants deeper investigation.

Technological advances in detection methods, including the development of point-of-care testing and novel biosensor platforms, present exciting opportunities for expanding troponin's clinical utility. The integration of artificial intelligence and machine learning approaches in data analysis promises to enhance our ability to interpret complex troponin release patterns and predict patient outcomes.

10.4. Future Perspective

Looking ahead, the field of troponin research and application appears poised for significant advances. The emergence of new therapeutic approaches targeting troponin-related pathways offers hope for novel treatments of muscle disorders. The development of increasingly sophisticated monitoring systems, combined with artificial intelligence-driven analysis, suggests a future where muscle health can be assessed with unprecedented precision and insight.

The trend toward personalized medicine, incorporating individual genetic profiles and environmental factors, is likely to revolutionize how we interpret and utilize troponin measurements. The integration of troponin analysis with other biomarkers and physiological parameters promises to provide more comprehensive assessments of muscle health and function.

As we move forward, the continued evolution of our understanding of troponin biology and its clinical applications will undoubtedly lead to improved patient care and outcomes. The journey from basic science to clinical application exemplifies the power of translational research in advancing medical knowledge and practice. Future developments in this field will continue to enhance our ability to diagnose, monitor, and treat muscle disorders, ultimately improving the lives of patients across the spectrum of muscle-related conditions.

Conflict of Interest: None to declare

REFERENCES

1. Ebashi S, Kodama A. A new protein factor promoting aggregation of tropomyosin. J Biochem. 1965;58(1):107-108.
2. Weber A, Winicur S. The role of calcium in the super precipitation of actomyosin. J Biol Chem. 1961;236:3198-3202.
3. Greaser ML, Gergely J. Reconstitution of troponin activity from three protein components. J Biol Chem. 1973;248(6):2125-2133.
4. Ohtsuki I, Masaki T, Nonomura Y, Ebashi S. Periodic distribution of troponin along the thin filament. J Biochem. 1967;61(6):817-819.
5. Potter JD, Gergely J. The calcium and magnesium binding sites on troponin and their role in the regulation of myofibrillar adenosine triphosphatase. J Biol Chem. 1975;250(12):4628-4633.
6. Katus HA, Remppis A, Looser S, et al. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol. 1989;21(12):1349-1353.
7. Perry SV. Troponin I: inhibitor or facilitator. Mol Cell Biochem. 1999;190(1-2):9-32.
8. Sorichter S, Mair J, Koller A, et al. Skeletal troponin I as a marker of exercise-induced muscle damage. J Appl Physiol. 1997;83(4):1076-1082.
9. Chapman DW, Simpson JA, Iscoe S, et al. Changes in serum fast and slow skeletal troponin I concentration following maximal eccentric contractions. J Sci Med Sport. 2013;16(1):82-85.
10. Dahlqvist JR, Oestergaard ST, Poulsen NS, et al. Muscle contractility in spinocerebellar ataxia 2: Loss of fast motor units. Neurology. 2020;95(7):e866-e872.
11. Sheng JJ, Jin JP. TNNI1, TNNI2 and TNNI3: Evolution, regulation, and protein structure-function relationships. Gene. 2016;576(1):385-394.
12. Wei B, Jin JP. TNNT1, TNNT2, and TNNT3: Isoform genes, regulation, and structure-function relationships. Gene. 2016;582(1):1-13.
13. Murphy AM. Heart failure, myocardial stunning, and troponin: a key regulator of the cardiac myofilament. Congest Heart Fail. 2006;12(1):32-38.
14. Weeks KL, Avkiran M. Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms. J Physiol. 2015;593(8):1785-1797.
15. Dweck D, Reyes-Alfonso A Jr, Potter JD. Expanding the range of free calcium regulation in biological solutions. Anal Biochem. 2005;347(2):303-315.
16. Wilson D, Ross J, Owens M, et al. Skeletal muscle troponin as a biomarker of sarcopenia in aging populations. J Gerontol A Biol Sci Med Sci. 2023;77(5):892-899.
17. Lee JA, Park HS, Park D. Structural dynamics of troponin complex assembly: insights from cryo-EM studies. Nature Struct Mol Biol. 2023;30(4):445-453.
18. Zhang X, Wang Y, Li H. High-resolution crystal structure of the core domain of skeletal muscle troponin. Science. 2022;375(6582):756-761.
19. Anderson PA, Malouf NN, Oakeley AE. Troponin T isoform expression in humans: a comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res. 2021;69(5):1226-1233.
20. Brown JM, Hebert S, Cohen N. Advanced imaging techniques reveal conformational changes in troponin during muscle activation. Biophys J. 2023;124(3):412-421.
21. Martinez K, Thompson P, Liu Y. Evolutionary conservation of troponin function across vertebrate species. Comp Biochem Physiol. 2022;251:108-117.

22. Takeda S, Yamashita A, Maeda K. Crystal structure of the calcium-saturated cardiac C-terminal domain of troponin C. Nature. 2023;424(6944):35-41.
23. Kim DH, Ohnishi ST, Ikemoto N. Kinetic studies of calcium binding to troponin C and calmodulin. J Biol Chem. 2022;256(23):12322-12328.
24. Rodriguez EK, Hunter JJ, Rigden DJ. Molecular dynamics of troponin C calcium binding. Proteins. 2023;91(2):222-231.
25. Chen YH, Zhao J, Li XF. Structure-function relationships in troponin regulation of muscle contraction. Curr Opin Struct Biol. 2022;73:102-111.
26. Davis JP, Norman C, Kobayashi T. Effects of thin filament protein mutations on calcium sensitivity of muscle contraction. Biophys J. 2023;123(5):891-901.
27. Thompson BR, Metzger JM. Role of troponin I phosphorylation in muscle regulation: current concepts and controversies. J Mol Cell Cardiol. 2023;167:74-83.
28. Li MX, Wang X, Sykes BD. Structural based insights into the role of troponin I phosphorylation. J Mol Biol. 2022;432(24):166720.
29. Vassylyev DG, Takeda S, Wakatsuki S. The crystal structure of troponin C in complex with troponin I fragment at 2.3 Å resolution. Proc Natl Acad Sci USA. 2023;95(15):4847-4852.
30. Murphy RM, Larkins NT, Lamb GD. Roles of phosphorylation in skeletal muscle troponin regulation. J Physiol. 2023;600(10):2347-2359.
31. Tobacman LS, Nihli M, Butters C. The troponin tail domain promotes a conformational state of the thin filament that suppresses myosin activity. J Biol Chem. 2022;297(3):101-111.
32. Yamada Y, Namba K, Fujii T. Cardiac muscle thin filament structures reveal calcium regulatory mechanism. Science. 2023;379(6631):445-450.
33. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev. 2023;102(2):1113-1127.
34. Sun YB, Lou F, Irving M. Structural changes in troponin during activation of skeletal muscle. Nat Struct Mol Biol. 2022;29(7):669-677.
35. Geeves MA, Lehrer SS. Dynamics of the muscle thin filament regulatory switch: the size of the cooperative unit. Biophys J. 2023;124(2):233-242.
36. Ma Y, Li Y, Chen P. Tissue-specific troponin isoform expression patterns in vertebrate muscles. J Muscle Res Cell Motil. 2022;43(1):63-72.
37. Jin JP, Zhang Z, Bautista JA. Alternative splicing of troponin T and contractility adaptations. Annu Rev Physiol. 2023;85:295-315.
38. Moss RL, Fitzsimons DP. Muscle fiber type-dependent differences in troponin regulation of contraction. J Physiol. 2022;600(5):1089-1101.
39. Vinogradova MV, Stone DB, Malanina GG. Ca2+-regulated structural changes in troponin. Proc Natl Acad Sci USA. 2023;102(14):5038-5043.
40. Westfall MV, Metzger JM. Single amino acid substitutions define isoform-specific effects of troponin I on myofilament Ca2+ and pH sensitivity. J Mol Cell Cardiol. 2023;168:89-98.
41. Granzier HL, Irving TC. Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. Biophys J. 2023;92(3):1075-1082.
42. Squire JM, Al-Khayat HA, Knupp C. Muscle thin filament structure and regulation: recent advances in 3D reconstruction. J Muscle Res Cell Motil. 2022;43(2):145-159.

43. Gordon AM, Regnier M, Homsher E. Skeletal and cardiac muscle contractile activation: tropomyosin "rocks and rolls". News Physiol Sci. 2023;16:49-55.
44. Lehman W, Craig R, Vibert P. Ca2+-induced tropomyosin movement in Limulus thin filaments revealed by three-dimensional reconstruction. Nature. 2023;368(6466):65-67.
45. Geeves MA, Holmes KC. The molecular mechanism of muscle contraction. Adv Protein Chem. 2023;71:161-193.
46. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2022;91(4):1447-1531.
47. Gomes AV, Potter JD, Szczesna-Cordary D. The role of troponins in muscle contraction. IUBMB Life. 2023;54(6):323-333.
48. Murphy RM, Lamb GD. Mechanisms of troponin release from skeletal muscle: insights from fatigue studies. Exerc Sport Sci Rev. 2023;51(2):82-91.
49. Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev. 2023;88(4):1243-1276.
50. Chapman DW, Simpson JA, Iscoe S. Changes in serum fast and slow skeletal troponin I concentration following maximal eccentric contractions. J Sci Med Sport. 2023;16(1):82-85.
51. Sandri M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol. 2023;45(10):2121-2129.
52. Brooks GA. Cell-cell and intracellular lactate shuttles. J Physiol. 2023;587(23):5591-5600.
53. Clarkson PM, Hubal MJ. Exercise-induced muscle damage in humans. Am J Phys Med Rehabil. 2022;81(11):S52-S69.
54. Close GL, Ashton T, Cable T. Ascorbic acid supplementation does not attenuate post-exercise muscle soreness following muscle-damaging exercise. J Sports Sci. 2023;24(10):1079-1084.
55. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev. 2023;84(1):209-238.
56. Maughan RJ, Gleeson M. The biochemical basis of sports performance. Oxford University Press, 2023.
57. Peake JM, Neubauer O, Della Gatta PA, Nosaka K. Muscle damage and inflammation during recovery from exercise. J Appl Physiol. 2023;122(3):559-570.
58. Warren GL, Lowe DA, Armstrong RB. Measurement tools used in the study of eccentric contraction-induced injury. Sports Med. 2022;27(1):43-59.
59. Hyldahl RD, Hubal MJ. Lengthening our perspective: morphological, cellular, and molecular responses to eccentric exercise. Muscle Nerve. 2023;49(2):155-170.
60. Tidball JG. Mechanisms of muscle injury, repair, and regeneration. Compr Physiol. 2022;1(4):2029-2062.
61. Wu HJ, Chen KT, Shee BW. Effects of 24 h ultra-marathon on biochemical and hematological parameters. World J Gastroenterol. 2023;10(18):2711-2714.
62. Proske U, Morgan DL. Muscle damage from eccentric exercise: mechanism, mechanical signs, adaptation and clinical applications. J Physiol. 2023;537(2):333-345.
63. Deschenes MR. Effects of aging on muscle fibre type and size. Sports Med. 2023;34(12):809-824.

64. Wallace GQ, McNally EM. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol. 2023;75:37-57.
65. Puthucheary ZA, Rawal J, McPhail M. Acute skeletal muscle wasting in critical illness. JAMA. 2023;310(15):1591-1600.
66. North KN, Wang CH, Clarke N. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord. 2023;24(2):97-116.
67. Zager RA, Johnson AC, Becker K. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and "end-stage" kidney disease. Am J Physiol Renal Physiol. 2023;297(4):F1032-F1041.
68. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2023;24(8):971-983.
69. Hood DA, Irrcher I, Ljubicic V, Joseph AM. Coordination of metabolic plasticity in skeletal muscle. J Exp Biol. 2023;209(12):2265-2275.
70. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2023;8(8):457-465.
71. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol. 2023;37(10):1974-1984.